Dynavax Soars 40% On Positive Phase 3 Hepatitis B Results

Today, shares of Dynavax Technologies (DVAX) soared 40% after the company reported that it had obtained positive phase 3 results for its Hepatitis B trial. This phase 3 trial looked at both safety and immunogenicity of the vaccine HEPISLAV-B.